In the realm of endoscopic surgeries, surgeons often grapple with the arduous task of distinguishing between various types of tissues. This challenge stems from the inherent limitations of visual contrast and the absence of tactile feedback. The prevailing imaging solutions encounter the following formidable hurdles:
Specialization Dilemma. Presently, healthcare institutions employ an array of distinct devices tailored for specific endoscopic visualization purposes. These endoscopy systems are meticulously crafted for singular techniques, offering only a solitary visualization capability each. Consequently, the availability of advanced imaging tools is remarkably constrained, severely limiting the wealth of information at a surgeon's disposal. To secure access to these advanced endoscopy systems, hospitals are compelled to acquire a multitude of devices, which invariably translates to elevated expenditure on both procurement and maintenance. This mounting financial burden not only inflates capital costs but also escalates operating expenses. Regrettably, the tight budgets of healthcare facilities hinder their ability to adopt and implement advanced visualization methods.
Precision is paramount in cystoscopies for bladder cancer, yet the grim reality persists - false negative rates can soar to a staggering 20%. In practical terms, this means that surgeons often fail to detect cancerous tissue, thereby setting the stage for cancer recurrence. In the realm of bladder cancer alone, a daunting 300,000 patients annually grapple with the burden of relapses in the European Union and the United States, with an equally concerning 150,000 enduring the harrowing progression of the disease.
The repercussions are far-reaching, as they extend beyond health concerns, significantly impacting both longevity and the overall quality of life. The ripple effect of repeated hospital visits and surgical interventions adds a substantial economic strain on patients and/or healthcare systems.
Yet, there is hope. Reducing cancer recurrence and progression rates through endoscopic surgery holds the promise of extending lives, enhancing the quality of life, and yielding substantial economic benefits. This translates to fewer hospital visits, a reduced need for surgeries, and a brighter future for patients.
Contrast. Present-day endoscopic systems grapple with a fundamental constraint: the inability to image using multiple contrast agents in parallel. This limitation compels surgeons to make a crucial choice, selecting just one imaging approach before the operation commences. However, the emergence of a variety of contrast solutions, some freshly approved by the FDA and others awaiting approval, unlocks a realm of unparalleled potential for achieving successful treatments.
Challenging Scan Times. Elevating accuracy often comes at a cost - an extended endoscopic scan time. This delay hinders surgeons from making swift, informed decisions, rendering existing systems inadequate for real-time imaging.
Thericon’s rMSI endoscopy system offers advanced performance to the surgeons, better treatment to the patients, and reduced costs to hospitals and healthcare systems.
